Patents by Inventor Thomas P. Dooley

Thomas P. Dooley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9616052
    Abstract: The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist. The invention provides methods for treating psychiatric condition or disorder or the symptoms thereof, including acute anxiety and panic comprising administering a pharmaceutical composition consisting essentially of a beta adrenergic receptor antagonist drug and an antiemetic muscarinic receptor antagonist drug in a therapeutically effective amount to stop or reduce the symptoms of anxiety and/or panic. The pharmaceutical compositions are administered as treatments immediately in advance of, at the onset of, or during an acute anxiety and/or panic episode.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: April 11, 2017
    Inventor: Thomas P. Dooley
  • Publication number: 20170049757
    Abstract: The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist. The invention provides methods for treating psychiatric condition or disorder or the symptoms thereof, including acute anxiety and panic comprising administering a pharmaceutical composition consisting essentially of a beta adrenergic receptor antagonist drug and an antiemetic muscarinic receptor antagonist drug in a therapeutically effective amount to stop or reduce the symptoms of anxiety and/or panic. The pharmaceutical compositions are administered as treatments immediately in advance of, at the onset of, or during an acute anxiety and/or panic episode.
    Type: Application
    Filed: November 8, 2016
    Publication date: February 23, 2017
    Inventor: Thomas P. DOOLEY
  • Patent number: 9517231
    Abstract: The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist. The invention provides methods for treating psychiatric condition or disorder or the symptoms thereof, including acute anxiety and panic comprising administering a pharmaceutical composition consisting essentially of a beta adrenergic receptor antagonist drug and an antiemetic muscarinic receptor antagonist drug in a therapeutically effective amount to stop or reduce the symptoms of anxiety and/or panic. The pharmaceutical compositions are administered as treatments immediately in advance of, at the onset of, or during an acute anxiety and/or panic episode.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: December 13, 2016
    Inventor: Thomas P. Dooley
  • Patent number: 9446030
    Abstract: The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist. The invention provides methods for treating psychiatric condition or disorder or the symptoms thereof, including acute anxiety and panic comprising administering a pharmaceutical composition consisting essentially of a beta adrenergic receptor antagonist drug and an antiemetic muscarinic receptor antagonist drug in a therapeutically effective amount to stop or reduce the symptoms of anxiety and/or panic. The pharmaceutical compositions are administered as treatments immediately in advance of, at the onset of, or during an acute anxiety and/or panic episode.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: September 20, 2016
    Inventor: Thomas P. Dooley
  • Publication number: 20160022652
    Abstract: The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist. The invention provides methods for treating psychiatric condition or disorder or the symptoms thereof, including acute anxiety and panic comprising administering a pharmaceutical composition consisting essentially of a beta adrenergic receptor antagonist drug and an antiemetic muscarinic receptor antagonist drug in a therapeutically effective amount to stop or reduce the symptoms of anxiety and/or panic. The pharmaceutical compositions are administered as treatments immediately in advance of, at the onset of, or during an acute anxiety and/or panic episode.
    Type: Application
    Filed: July 17, 2015
    Publication date: January 28, 2016
    Inventor: Thomas P. DOOLEY
  • Publication number: 20160022653
    Abstract: The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist. The invention provides methods for treating psychiatric condition or disorder or the symptoms thereof, including acute anxiety and panic comprising administering a pharmaceutical composition consisting essentially of a beta adrenergic receptor antagonist drug and an antiemetic muscarinic receptor antagonist drug in a therapeutically effective amount to stop or reduce the symptoms of anxiety and/or panic. The pharmaceutical compositions are administered as treatments immediately in advance of, at the onset of, or during an acute anxiety and/or panic episode.
    Type: Application
    Filed: July 20, 2015
    Publication date: January 28, 2016
    Inventor: Thomas P. DOOLEY
  • Patent number: 8735571
    Abstract: A composition of exceptionally dense chitosan and a novel method for producing the dense chitosan structure have been described. The novel production method employs coincident compression and vacuum on a neutralized chitosan polymer that results in an exceptionally dense chitosan film or membrane material. The dense chitosan film or membrane composition possesses multiple physical and clinically appealing qualities for a variety of medical applications on or in animals, mammals, or humans.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: May 27, 2014
    Assignee: Agenta Biotechnologies, Inc.
    Inventors: Arthur A. DeCarlo, April Ellis, Thomas P. Dooley, Maria Belousova
  • Publication number: 20130164311
    Abstract: A composition of exceptionally dense chitosan and a novel method for producing the dense chitosan structure have been described. The novel production method employs coincident compression and vacuum on a neutralized chitosan polymer that results in an exceptionally dense chitosan film or membrane material. The dense chitosan film or membrane composition possesses multiple physical and clinically appealing qualities for a variety of medical applications on or in animals, mammals, or humans.
    Type: Application
    Filed: December 22, 2011
    Publication date: June 27, 2013
    Applicant: Agenta Biotechnologies Inc.
    Inventors: Arthur A. DeCarlo, April Ellis, Thomas P. Dooley, Maria Belousova
  • Patent number: 7858105
    Abstract: Methods and formulations are provided to reduce pigmentation in skin, using an array of compounds selected from benzimidazoles, phenylthioureas, phenylthiols, phenylamines, bi- and multicyclic phenols, thiopheneamines, and benzothiamides. The compounds preferably inhibit pigment synthesis in melanocytes through the tyrosinase pathway. The methods can be used for lightening skin, and for treating uneven skin complexions which result from hyperpigmentation-related medical conditions such as melasma, age spots, freckles, ochronosis, and lentigo. The compounds can be used medically or cosmetically.
    Type: Grant
    Filed: September 8, 2008
    Date of Patent: December 28, 2010
    Assignee: Mediquest Therapeutics, Inc.
    Inventors: Thomas P. Dooley, Ernest V. Curto
  • Patent number: 7718185
    Abstract: Methods and formulations are provided to reduce pigmentation in skin, using an array of compounds selected from benzimidazoles, phenylthioureas, phenyltiols, phenylamines, bi- and multicyclic phenols, thiopheneamines, and benzothiamides. The compounds preferably inhibit pigment synthesis in melanocytes through the tyrosinase pathway. The methods can be used for lightening skin, and for treating uneven skin complexions which result from hyperpigmentation-related medical conditions such as melasma, age spots, freckles, ochronosis, and lentigo. The compounds can be used medically or cosmetically.
    Type: Grant
    Filed: September 8, 2008
    Date of Patent: May 18, 2010
    Assignee: MediQuest Therapeutics, Inc.
    Inventors: Thomas P. Dooley, Ernest V. Curto
  • Publication number: 20090023792
    Abstract: Methods and formulations are provided to reduce pigmentation in skin, using an array of compounds selected from benzimidazoles, phenylthioureas, phenyltiols, phenylamines, bi- and multicyclic phenols, thiopheneamines, and benzothiamides. The compounds preferably inhibit pigment systhesis in melanocytes through the tyrosinase pathway. The methods can be used for lightening skin, and for treating uneven skin complexions which result from hyperpigmentation-related medical conditions such as melasma, age spots, freckles, ochronosis, and lentigo. The compounds can be used medically or cosmetically.
    Type: Application
    Filed: September 8, 2008
    Publication date: January 22, 2009
    Applicant: Mediquest Therapeutics, Inc.
    Inventors: Thomas P. Dooley, Ernest V. Curto
  • Publication number: 20090023793
    Abstract: Methods and formulations are provided to reduce pigmentation in skin, using an array of compounds selected from benzimidazoles, phenylthioureas, phenyltiols, phenylamines, bi- and multicyclic phenols, thiopheneamines, and benzothiamides. The compounds preferably inhibit pigment systhesis in melanocytes through the tyrosinase pathway. The methods can be used for lightening skin, and for treating uneven skin complexions which result from hyperpigmentation-related medical conditions such as melasma, age spots, freckles, ochronosis, and lentigo. The compounds can be used medically or cosmetically.
    Type: Application
    Filed: September 8, 2008
    Publication date: January 22, 2009
    Applicant: Mediquest Therapeutics, Inc.
    Inventors: Thomas P. Dooley, Ernest V. Curto
  • Publication number: 20030232356
    Abstract: The present invention provides biomarker genes of mammalian skin-derived cells. A plurality of differentially-expressed up-regulated (signature) and down-regulated (anti-signature) biomarker genes for human keratinocytes, melanocytes, and fibroblasts are identified. Biomarker genes for cells at abnormal states such as melanoma cells are also provided. Further, there are provided analytical bioinformatic methods for identifying biomarker genes based on nucleic acid microarray data.
    Type: Application
    Filed: February 10, 2003
    Publication date: December 18, 2003
    Inventors: Thomas P. Dooley, Ernest V. Curto, Richard L. Davis
  • Publication number: 20030219393
    Abstract: Methods and formulations are provided to reduce pigmentation in skin, using an array of compounds selected from benzimidazoles, phenylthioureas, phenyltiols, phenylamines, bi- and multicyclic phenols, thiopheneamines, and benzothiamides. The compounds preferably inhibit pigment systhesis in melanocytes through the tyrosinase pathway. The methods can be used for lightening skin, and for treating uneven skin complexions which result from hyperpigmentation-related medical conditions such as melasma, age spots, freckles, ochronosis, and lentigo. The compounds can be used medically or cosmetically.
    Type: Application
    Filed: May 1, 2003
    Publication date: November 27, 2003
    Applicant: IntegriDerm, Inc.
    Inventors: Thomas P. Dooley, Ernest V. Curto
  • Publication number: 20030199558
    Abstract: Methods, compounds, and formulations are provided to reduce pigmentation in mammalian skin, comprising hydroxamic acid and its derivatives, and especially benzohydroxamic acid and its derivatives. The compounds preferably inhibit pigment synthesis in melanocytes through inhibition of melanocyte tyrosinase. The methods can be used for lightening skin, and for treating uneven skin complexions, which result from hyperpigmentation-related medical conditions such as melasma, age spots, freckles, ochronosis, and lentigo. The compounds can be used medically or cosmetically, and preferably as topical formulations.
    Type: Application
    Filed: December 23, 2002
    Publication date: October 23, 2003
    Applicant: Integriderm, Inc.
    Inventors: Thomas P. Dooley, Lin Cheng
  • Patent number: 6635423
    Abstract: The present invention is directed to methods for making and using informative nucleic acid arrays (e.g., DNA including cDNA, RNA, PNA) for research and other applications in various disciplines or areas of interest. Examples of such disciplines include, without limitation, dermatology, pharmacology, toxicology, oncology, gynecology, urology, gastroenterology, as well as studies of sentinel gene discovery, signature gene discovery, mechanism of action, drug screening, drug metabolism, etc. The informative nucleic acid arrays of the present invention may contain only the gene sequences that are of interest in a particular area of interest or application, and may exclude other gene sequences.
    Type: Grant
    Filed: January 16, 2001
    Date of Patent: October 21, 2003
    Assignee: Integriderm, Inc.
    Inventors: Thomas P. Dooley, Ernest V. Curto, Richard L. Davis, Jr.
  • Patent number: 6559295
    Abstract: The invention relates to the nucleic acid sequence and amino acid sequence of dihydrofolate reductase (DHFR) from mycobacteria and to expression of recombinant DHFR protein. Utilizing the recombinant protein, novel therapies and diagnostic strategies can be developed and selective antimycobacterial compositions can be designed and utilized to treat mycobacterial infections in patients. This invention includes all or portions of novel recombinant nucleic acids encoding DHFR for mycobacteria such as M. avium, to novel recombinant DHFR peptides produced by such sequences, and to vaccines, diagnostic kits, cells and therapies utilizing these peptides and nucleic acid sequences. The present invention relates to methods for using the sequences of the present invention to develop drugs specific to M. avium and other mycobacteria, to identify and sequence corresponding sequences in species other than M. avium, as well as diagnostic and treatment methods incorporating the disclosed sequences and peptides.
    Type: Grant
    Filed: August 12, 1999
    Date of Patent: May 6, 2003
    Assignee: Southern Research Institute
    Inventors: William W. Barrow, Sabrina Z. Van Ginkel, Thomas P. Dooley, William J. Suling
  • Publication number: 20020044914
    Abstract: Methods and formulations are provided to reduce pigmentation in skin, using an array of compounds selected from benzimidazoles, phenylthioureas, phenyltiols, phenylamines, bi- and multicyclic phenols, thiopheneamines, and benzothiamides. The compounds preferably inhibit pigment systhesis in melanocytes through the tyrosinase pathway. The methods can be used for lightening skin, and for treating uneven skin complexions which result from hyperpigmentation-related medical conditions such as melasma, age spots, freckles, ochronosis, and lentigo. The compounds can be used medically or cosmetically.
    Type: Application
    Filed: February 28, 2001
    Publication date: April 18, 2002
    Inventors: Thomas P. Dooley, Ernest V. Curto
  • Publication number: 20020035611
    Abstract: A system and method for providing an information network on the Internet is provided. The system includes a plurality of websites and at least one redirect assigned to each website. The websites each include a category, information about the category and a domain name that corresponds to the category. The redirect includes a URL redirect that directs a browser or a server to the assigned website. The method includes the steps of: (1) providing a plurality of websites; (2) providing each website with a category, information about the category, and a domain name that corresponds to the category; (3) providing at least one redirect assigned to each website; and (4) providing each redirect with a URL redirect that directs at least one of a browser and a server to the assigned website.
    Type: Application
    Filed: December 28, 2000
    Publication date: March 21, 2002
    Inventor: Thomas P. Dooley
  • Publication number: 20010046671
    Abstract: The present invention is directed to methods for making and using informative nucleic acid arrays (e.g., DNA including cDNA, RNA, PNA) for research and other applications in various disciplines or areas of interest. Examples of such disciplines include, without limitation, dermatology, pharmacology, toxicology, oncology, gynecology, urology, gastroenterology, as well as studies of sentinel gene discovery, signature gene discovery, mechanism of action, drug screening, drug metabolism, etc. The informative nucleic acid arrays of the present invention may contain only the gene sequences that are of interest in a particular area of interest or application, and may exclude other gene sequences.
    Type: Application
    Filed: January 16, 2001
    Publication date: November 29, 2001
    Inventors: Thomas P. Dooley, Ernest V. Curto, Richard L. Davis